bluebird bio (NASDAQ:BLUE) was up 0% during mid-day trading on Thursday . The stock traded as high as $190.50 and last traded at $189.30. Approximately 892,250 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 779,838 shares. The stock had previously closed at $189.30.
Several equities research analysts recently issued reports on BLUE shares. BidaskClub cut bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Friday, March 16th. ValuEngine upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald lowered their price objective on bluebird bio from $122.00 to $113.00 and set an “underweight” rating on the stock in a report on Thursday, February 22nd. SunTrust Banks lifted their price objective on bluebird bio to $232.00 and gave the stock a “buy” rating in a report on Thursday, April 19th. Finally, Bank of America lifted their price objective on bluebird bio from $185.00 to $218.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $195.80.
Get bluebird bio alerts:The stock has a market cap of $9.49 billion, a P/E ratio of -23.83 and a beta of 2.17.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.01) by ($0.30). The firm had revenue of $15.96 million for the quarter, compared to analysts’ expectations of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm’s quarterly revenue was up 133.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.68) EPS. equities research analysts forecast that bluebird bio will post -9.33 EPS for the current year.
In other news, Director Mark Vachon sold 6,000 shares of bluebird bio stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the sale, the director now owns 7,000 shares of the company’s stock, valued at approximately $1,500,660. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Philip D. Gregory sold 2,250 shares of bluebird bio stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $200.00, for a total transaction of $450,000.00. Following the sale, the insider now directly owns 32,522 shares in the company, valued at approximately $6,504,400. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,250 shares of company stock worth $8,269,990. Corporate insiders own 3.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in BLUE. Two Sigma Advisers LP raised its position in shares of bluebird bio by 3,004.0% during the 4th quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock valued at $82,371,000 after buying an additional 447,600 shares during the period. Redmile Group LLC purchased a new stake in bluebird bio in the fourth quarter valued at approximately $46,270,000. BlackRock Inc. raised its position in bluebird bio by 6.4% in the fourth quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after purchasing an additional 231,697 shares during the period. Franklin Resources Inc. raised its position in bluebird bio by 41.3% in the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after purchasing an additional 200,900 shares during the period. Finally, Carillon Tower Advisers Inc. purchased a new stake in bluebird bio in the fourth quarter valued at approximately $27,213,000.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent �-thalassemia and severe sickle cell disease.
No comments:
Post a Comment